uniQure's (QURE) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of uniQure (NASDAQ:QURE - Free Report) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $38.00 target price on the biotechnology company's stock.

A number of other brokerages have also recently issued reports on QURE. HC Wainwright reissued a "buy" rating and set a $70.00 price objective on shares of uniQure in a report on Monday, April 21st. Wells Fargo & Company cut their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. StockNews.com raised shares of uniQure to a "sell" rating in a research note on Tuesday, March 11th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $38.80.

uniQure Stock Performance

Shares of NASDAQ QURE traded up $0.53 during trading hours on Tuesday, reaching $12.78. The stock had a trading volume of 3,139,385 shares, compared to its average volume of 1,861,654. The company has a market cap of $700.04 million, a price-to-earnings ratio of -2.58 and a beta of 0.10. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The business's fifty day moving average is $12.22 and its two-hundred day moving average is $12.09. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, research analysts expect that uniQure will post -3.75 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, CFO Christian Klemt sold 2,916 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the transaction, the chief financial officer now owns 155,168 shares in the company, valued at $1,756,501.76. This trade represents a 1.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 26,727 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $285,978.90. Following the completion of the sale, the chief executive officer now directly owns 571,188 shares of the company's stock, valued at approximately $6,111,711.60. The trade was a 4.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,830 shares of company stock worth $961,401. Insiders own 4.74% of the company's stock.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently bought and sold shares of QURE. Invesco Ltd. raised its position in shares of uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after buying an additional 502,684 shares in the last quarter. Sanders Morris Harris LLC raised its position in shares of uniQure by 50.0% in the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock valued at $1,803,000 after buying an additional 34,034 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of uniQure during the 3rd quarter worth approximately $7,360,000. Oppenheimer & Co. Inc. acquired a new stake in shares of uniQure during the 4th quarter worth approximately $320,000. Finally, Palumbo Wealth Management LLC acquired a new position in uniQure during the fourth quarter valued at approximately $437,000. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.